Selective influence on contextual memory: physiochemical properties associated with selectivity of benzodiazepine ligands at GABAA receptors containing the alpha5 subunit.

Ligands that bind to the benzodiazepine binding site on the GABA A receptor can attenuate or potentiate cognition. To investigate this property, the chemical determinants favoring selective binding or selective activation of the alpha5beta2gamma2 and alpha1beta2gamma2 GABA A receptor isoforms were examined. A 3D-pharmacophore, developed from a diverse set of BDZR ligands, was used as an initial basis for multivariate discriminant, fragment, and 3D-quantitative structure-activity relationship analyses, which formed the criteria for selection of additional compounds for study. We found that the electrostatic potential near the ligands' terminal substituent correlated with its binding selectivity toward the alpha5beta2gamma2 versus alpha1beta2gamma2 isoform; while the fragment length and frontier molecular orbital energetics correlated with a compounds influence on electrophysiological activity. Compounds with promising alpha5 profiles were further assessed for their ability to attenuate scopolamine-induced contextual memory impairment in mice. Surprisingly, both weak inverse agonist and antagonists that display binding selectivity toward the alpha5beta2gamma2 isoform were able to attenuate contextual memory impairment.

[1]  Dongmei Cheng,et al.  Inhibition of CYP2B4 by 2-ethynylnaphthalene: evidence for the co-binding of substrate and inhibitor within the active site. , 2007, Archives of biochemistry and biophysics.

[2]  D. Stephens,et al.  An inverse agonist selective for α5 subunit-containing GABAA receptors improves encoding and recall but not consolidation in the Morris water maze , 2006, Psychopharmacology.

[3]  C. Adkins,et al.  Effect of alpha subunit on allosteric modulation of ion channel function in stably expressed human recombinant gamma-aminobutyric acid(A) receptors determined using (36)Cl ion flux. , 2001, Molecular pharmacology.

[4]  R. Rubin,et al.  Immunohistochemical Study of GABAAReceptor β2/3 Subunits in the Hippocampal Formation of Aged Brains with Alzheimer-Related Neuropathologic Changes , 1997, Experimental Neurology.

[5]  Matthieu Hamel,et al.  Journal of Medicinal Chemistry , 2010 .

[6]  R. Mckernan,et al.  theta, a novel gamma-aminobutyric acid type A receptor subunit. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[7]  U. Rudolph,et al.  GABA(A)-receptor subtypes: a new pharmacology. , 2001, Current opinion in pharmacology.

[8]  R. Horowski,et al.  SEVERE ANXIETY INDUCED BY FG 7142, A β-CARBOLINE LIGAND FOR BENZODIAZEPINE RECEPTORS , 1983, The Lancet.

[9]  T. Liljefors,et al.  Structure-activity relationships and molecular modeling analysis of flavonoids binding to the benzodiazepine site of the rat brain GABA(A) receptor complex. , 1999, Journal of medicinal chemistry.

[10]  S L Shafer,et al.  Unraveling the identity of benzodiazepine binding sites in rat hipppocampus and olfactory bulb. , 2000, European journal of pharmacology.

[11]  Darren R. Flower,et al.  Drug design : cutting edge approaches , 2002 .

[12]  R. Mckernan,et al.  Which GABAA-receptor subtypes really occur in the brain? , 1996, Trends in Neurosciences.

[13]  Sami I. Horih Basic Neurochemistry , 1989, Neurology.

[14]  M. Fanselow,et al.  Mice Lacking the β3 Subunit of the GABAA Receptor Have the Epilepsy Phenotype and Many of the Behavioral Characteristics of Angelman Syndrome , 1998, The Journal of Neuroscience.

[15]  R. Bolles,et al.  Naloxone and shock-elicited freezing in the rat. , 1979 .

[16]  H. Kubinyi Strategies and recent technologies in drug discovery. , 1995, Die Pharmazie.

[17]  Gerhard Klebe,et al.  Comparative Molecular Similarity Index Analysis (CoMSIA) to study hydrogen-bonding properties and to score combinatorial libraries , 1999, J. Comput. Aided Mol. Des..

[18]  T. Duka,et al.  The effects of a benzodiazepine receptor antagonist β-carboline ZK-93426 on scopolamine-induced impairment on attention, memory and psychomotor skills , 1996, Psychopharmacology.

[19]  Xiaohui He,et al.  Pharmacophore/Receptor Models for GABAA/BzR Subtypes (α1β3γ2, α5β3γ2, and α6β3γ2) via a Comprehensive Ligand-Mapping Approach , 2000 .

[20]  W. Sieghart,et al.  Are GABAA Receptors Containing α5 Subunits Contributing to the Sedative Properties of Benzodiazepine Site Agonists? , 2008, Neuropsychopharmacology.

[21]  E. Sigel Properties of single sodium channels translated by Xenopus oocytes after injection with messenger ribonucleic acid. , 1987, The Journal of physiology.

[22]  K Abe,et al.  Effects of S-8510, a novel benzodiazepine receptor partial inverse agonist, on basal forebrain lesioning-induced dysfunction in rats. , 1998, European journal of pharmacology.

[23]  J. Benson,et al.  Benzodiazepine actions mediated by specific γ-aminobutyric acidA receptor subtypes , 1999, Nature.

[24]  James J. P. Stewart,et al.  MOPAC: A semiempirical molecular orbital program , 1990, J. Comput. Aided Mol. Des..

[25]  M. Sarter,et al.  Trans-synaptic stimulation of cortical acetylcholine and enhancement of attentional functions: a rational approach for the development of cognition enhancers , 1997, Behavioural Brain Research.

[26]  M. Davies,et al.  Evidence for central benzodiazepine receptor heterogeneity from behavior tests , 1994, Pharmacology Biochemistry and Behavior.

[27]  S. File Proconvulsant action of CGS 8216 , 1983, Neuroscience Letters.

[28]  K. Kawasaki,et al.  A novel benzodiazepine inverse agonist, S-8510, as a cognitive enhancer , 1996, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[29]  R. Mckernan,et al.  u, a novel g-aminobutyric acid type A receptor subunit , 1999 .

[30]  M. Filizola,et al.  Benzodiazepine-Induced Hyperphagia: Development and Assessment of a 3D Pharmacophore By Computational Methods , 2000, Journal of biomolecular structure & dynamics.

[31]  G. Dawson,et al.  3-Phenyl-6-(2-pyridyl)methyloxy-1,2,4-triazolo[3,4-a]phthalazines and Analogues: High-Affinity γ-Aminobutyric Acid-A Benzodiazepine Receptor Ligands with α2, α3, and α5-Subtype Binding Selectivity over α1 , 2004 .

[32]  R. Lin,et al.  Influence of benzodiazepine binding site ligands on fear-conditioned contextual memory. , 2001, European journal of pharmacology.

[33]  G. Loew,et al.  Development and assessment of a 3D pharmacophore for ligand recognition of BDZR/GABAA receptors initiating the anxiolytic response. , 2000, Bioorganic & medicinal chemistry.

[34]  P. Skolnick,et al.  Synthesis and pharmacological properties of novel 8-substituted imidazobenzodiazepines: high-affinity, selective probes for alpha 5-containing GABAA receptors. , 1996, Journal of medicinal chemistry.

[35]  D. A. Bennett Pharmacology of the pyrazolo-type compounds: Agonist, antagonist and inverse agonist actions , 1987, Physiology & Behavior.

[36]  K. Koehler,et al.  Development of a comprehensive pharmacophore model for the benzodiazepine receptor. , 1995, Drug design and discovery.

[37]  G. Dawson,et al.  L-655,708 enhances cognition in rats but is not proconvulsant at a dose selective for α5-containing GABAA receptors , 2006, Neuropharmacology.

[38]  S. Martelli,et al.  Rational design, synthesis and biological evaluation of thiadiazinoacridines: a new class of antitumor agents. , 2003, Bioorganic & medicinal chemistry.

[39]  M. Letizia Barreca,et al.  Pharmacophore Modeling as an Efficient Tool in the Discovery of Novel Noncompetitive AMPA Receptor Antagonists , 2003, J. Chem. Inf. Comput. Sci..

[40]  J. Deschamps,et al.  Synthesis, in vitro affinity, and efficacy of a bis 8-ethynyl-4H-imidazo[1,5a]- [1,4]benzodiazepine analogue, the first bivalent alpha5 subtype selective BzR/GABA(A) antagonist. , 2003, Journal of medicinal chemistry.

[41]  A. Guidotti,et al.  Benzodiazepines on trial: a research strategy for their rehabilitation. , 1996, Trends in pharmacological sciences.

[42]  G. Dawson,et al.  Modulation of Long-term Potentiation in CA1 Region of Mouse Hippocampal Brain Slices by GABAA Receptor Benzodiazepine Site Ligands , 1997, Neuropharmacology.

[43]  R. Mckernan,et al.  Density and pharmacology of α5 subunit-containing GABAA receptors are preserved in hippocampus of Alzheimer’s disease patients , 2000, Neuroscience.

[44]  Eric A. Barnard,et al.  Analysis of the Set of GABAA Receptor Genes in the Human Genome* , 2004, Journal of Biological Chemistry.

[45]  R. Maynard,et al.  The Pharmacological Basis of Therapeutics. 9th ed , 1997 .

[46]  A. Verloop,et al.  Development and Application of New Steric Substituent Parameters in Drug Design , 1976 .

[47]  U. Rudolph,et al.  Analysis of GABAA receptor function and dissection of the pharmacology of benzodiazepines and general anesthetics through mouse genetics. , 2004, Annual review of pharmacology and toxicology.

[48]  M. Vaswani,et al.  Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review , 2003, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[49]  C. Broka,et al.  Rational design of 6-methylsulfonylindoles as selective cyclooxygenase-2 inhibitors. , 2004, Bioorganic & medicinal chemistry letters.

[50]  G. Klebe,et al.  Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. , 1994, Journal of medicinal chemistry.

[51]  R. Mckernan,et al.  Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABAA receptor α1 subtype , 2000, Nature Neuroscience.

[52]  T. Delorey,et al.  Determinants of recognition of ligands binding to benzodiazepine receptor/GABA(A) receptors initiating sedation. , 2000, European journal of pharmacology.

[53]  Dongmei Cheng,et al.  Inhibition of CYP2B4 by the mechanism-based inhibitor 2-ethynylnaphthalene: inhibitory potential of 2EN is dependent on the size of the substrate. , 2007, Archives of biochemistry and biophysics.

[54]  H. Kubinyi,et al.  Three-dimensional quantitative similarity-activity relationships (3D QSiAR) from SEAL similarity matrices. , 1998, Journal of medicinal chemistry.

[55]  G. Dawson,et al.  The proconvulsant effects of the GABAA α5 subtype-selective compound RY-080 may not be α5-mediated , 2006 .

[56]  I. Izquierdo,et al.  Endogenous benzodiazepine modulation of memory processes , 1990, Neuroscience & Biobehavioral Reviews.

[57]  K. Vogt,et al.  Trace fear conditioning involves hippocampal α5 GABAA receptors , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[58]  G. Dawson,et al.  6,7-Dihydro-2-benzothiophen-4(5H)-ones: a novel class of GABA-A alpha5 receptor inverse agonists. , 2002, Journal of medicinal chemistry.

[59]  C. Adkins,et al.  Effect of α Subunit on Allosteric Modulation of Ion Channel Function in Stably Expressed Human Recombinant γ-Aminobutyric AcidA Receptors Determined Using36Cl Ion Flux , 2001 .

[60]  M. Davies,et al.  Putative benzodiazepine partial agonists demonstrate receptor heterogeneity , 1996, Pharmacology Biochemistry and Behavior.

[61]  Structural Elements of the γ-Aminobutyric Acid Type A Receptor Conferring Subtype Selectivity for Benzodiazepine Site Ligands* , 1999, The Journal of Biological Chemistry.

[62]  K. Fuchs,et al.  Endogenous [3H]flunitrazepam binding in human embryonic kidney cell line 293. , 1995, European journal of pharmacology.

[63]  P. Whitehouse The cholinergic deficit in Alzheimer's disease. , 1998, The Journal of clinical psychiatry.

[64]  K. Inoguchi,et al.  Rational design, discovery, and synthesis of a novel series of potent growth hormone secretagogues. , 2001, Journal of medicinal chemistry.

[65]  F. Helmstetter,et al.  Effects of Hippocampal Injections of a Novel Ligand Selective for the α5β2γ2 Subunits of the GABA/Benzodiazepine Receptor on Pavlovian Conditioning , 2002, Neurobiology of Learning and Memory.

[66]  M. Sarter,et al.  Bidirectional effects of β-carbolines and benzodiazepines on cognitive processes , 1987, Brain Research Bulletin.

[67]  Alexander Wlodawer,et al.  Rational approach to AIDS drug design through structural biology. , 2002, Annual review of medicine.

[68]  G. Pei,et al.  3D-QSAR model of flavonoids binding at benzodiazepine site in GABAA receptors. , 2001, Journal of medicinal chemistry.

[69]  M. Baraldi,et al.  Endozepines in recurrent stupor. , 2005, Sleep medicine reviews.

[70]  J. Rossier,et al.  Benzodiazepine impairs and β-carboline enhances performance in learning and memory tasks , 1986, Nature.

[71]  E. Perry,et al.  Convergent cholinergic activities in aging and Alzheimer's disease , 1992, Neurobiology of Aging.

[72]  M. Evans,et al.  Midazolam inhibits long-term potentiation through modulation of GABAA receptors , 1996, Neuropharmacology.

[73]  N Collinson,et al.  An Inverse Agonist Selective for α5 Subunit-Containing GABAA Receptors Enhances Cognition , 2006, Journal of Pharmacology and Experimental Therapeutics.

[74]  P. Seeburg,et al.  Functional Expression of GABAA Chloride Channels and Benzodiazepine Binding Sites in Baculovirus Infected Insect Cells , 1992, Bio/Technology.

[75]  D. Burt,et al.  GABAA receptor subtypes: from pharmacology to molecular biology , 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[76]  B. R. Sastry,et al.  Benzodiazepine involvement in LTP of the GABA-ergic IPSC in rat hippocampal CA1 neurons , 2005, Brain Research.

[77]  H. Möhler,et al.  GABAA receptor diversity and pharmacology , 2006, Cell and Tissue Research.

[78]  R. Olsen,et al.  Ethanol potently and competitively inhibits binding of the alcohol antagonist Ro15-4513 to α4/6β3δ GABAA receptors , 2006 .

[79]  Timothy M. DeLorey,et al.  GABA and Glycine , 1999 .

[80]  Gerhard Trube,et al.  The effect of subunit composition of rat brain GABAA receptors on channel function , 1990, Neuron.

[81]  M. Filizola,et al.  Development of a 3D pharmacophore for nonspecific ligand recognition of α1, α2, α3, α5, and α6 containing gabaA/benzodiazepine receptors , 2000 .

[82]  G. Dawson,et al.  Identification of a Novel, Selective GABAA α5 Receptor Inverse Agonist Which Enhances Cognition , 2003 .

[83]  N. Bogdanovic,et al.  GABA transporters (GAT-1) in Alzheimer's disease , 1999, Journal of Neural Transmission.